Hyun S. Kim

Hyun S. Kim

Auto-generated profile, based on publicly available information

Hyun S. Kim

Emory University School of Medicine

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2014 in Journal of Vascular and Interventional Radiology
Verified
Journal Article
Closed access
JCJuan Camacho
Juan Camacho
NKNima Kokabi
Nima Kokabi
MXMinzhi Xing
Minzhi Xing
HPHasmukh J. Prajapati
Hasmukh J. Prajapati
BEBassel El-Rayes
Bassel El-Rayes
HKHyun S. Kim
Hyun S. Kim

1 May 2015 in Journal of Vascular and Interventional Radiology
Verified
Journal Article
Closed access
JCJuan Camacho
Juan Camacho
NKNima Kokabi
Nima Kokabi
MXMinzhi Xing
Minzhi Xing
VMViraj A. Master
Viraj A. Master
JPJohn G. Pattaras
John G. Pattaras
HKHyun S. Kim
Hyun S. Kim

6 April 2015 in Cancer
Verified
Journal Article
Open access
PDF file
NKNima Kokabi
Nima Kokabi
JCJuan Camacho
Juan Camacho
MXMinzhi Xing
Minzhi Xing
BEBassel F. El‐Rayes
Bassel F. El‐Rayes
JSJames R. Spivey
James R. Spivey
HKHyun S. Kim
Hyun S. Kim
BACKGROUND: The safety and efficacy of yttrium 90 (90Y) therapy for unresectable infiltrative hepatocellular carcinoma (HCC) with portal vein thrombosis (PVT) requires further evaluation.METHODS: A prospective, single‐center safety and feasibility study recruited patients with unresectable (Barcelona Clinic Liver Cancer stage C) infiltrative HCC with PVT. Safety was assessed according to Common Terminology Criteria for Adverse Events version 4.0. Overall survival (OS) and time to progression (TTP) were measured from the first 90Y therapy. Survival analysis was performed with Kaplan‐Meier estimation. Prognostic factors were tested with a log‐rank test and Cox proportional regression analysis.RESULTS: Overall, 45 patients were recruited, and 30 patients who met the study's inclusion criteria underwent glass‐based 90Y therapy. Four patients (13%) had transient hepatobiliary toxicity (grade ≥ 2). Ten patients (33%) had related emergency department visits, with 5 patients (17%) requiring short‐term hospitalization. No radiation pneumonitis, gastrointestinal ulceration, or procedure‐related mortality occurred. The median OS was 13 months (95% confidence interval, 4.4‐22 months) with a TTP of 9 months (95% confidence interval, 6.2‐13.1 months). Absence of ascites, an international normalized ratio < 1.2, an Eastern Cooperative Oncology Group (ECOG) performance status of 0, Child‐Pugh class A, a macroaggregated albumin lung shunt fraction (LSF) < 10%, and no hepatobiliary toxicity were significant predictors of prolonged OS according to a univariate analysis (P < .05). A multivariate analysis found an ECOG performance status of 0, Child‐Pugh class A, an LSF < 10%, and lack of transient hepatobiliary toxicity (grade ≥ 2) to be independent predictors of prolonged OS (P < .05). An ECOG performance status of 0, Child‐Pugh class A, and an LSF < 10% were also predictors of prolonged TTP according to the multivariate analysis (P < .05).CONCLUSIONS: In patients with unresectable infiltrative HCC and PVT, 90Y therapy appears to be a safe and viable therapy. Cancer 2015;121:2164–2174. © 2015 American Cancer Society.


1 February 2014 in Journal of Vascular and Interventional Radiology
Verified
Journal Article
Closed access
NKNima Kokabi
Nima Kokabi
JGJames R. Galt
James R. Galt
MXMinzhi Xing
Minzhi Xing
JCJuan Camacho
Juan Camacho
BBBruce J. Barron
Bruce J. Barron
HKHyun S. Kim
Hyun S. Kim

24 April 2014 in Journal of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
MXMinzhi Xing
Minzhi Xing
DKDavid A. Kooby
David A. Kooby
BEBassel F. El-Rayes
Bassel F. El-Rayes
NKNima Kokabi
Nima Kokabi
JCJuan C. Camacho
Juan C. Camacho
HKHyun S. Kim
Hyun S. Kim